Bringer Ingelheim, a medical fast reading society, gave up Bi 1467335 for NASH indications

[December 19, 2019 / list of medical information] the standards for the speciation and valence determination of mercury and arsenic in the new edition of Pharmacopoeia are to be upgraded; Fujifilm acquires Hitachi medical imaging business; vosevi is approved for listing in China; Novartis terminates the development of sting agonists Daily fresh medicine news, speed reading club and you pay attention to! On September 19, the national health and Health Commission issued a document saying that nine departments recently printed and issued the implementation opinions on expanding the regional scope of national organization drug centralized purchase and use pilot (medical insurance Fa [2019] No 56), expanding the regional scope of national organization drug centralized purchase and use pilot from "4 + 7" cities and cities to the whole country (National Health and Health Commission) On August 18, centering closely on the overall goal of the 13th five year plan for national drug safety, taking the establishment of "the most rigorous standard" as the criterion and benchmarking the international advanced standards, the State Pharmacopoeia Commission released 2322 "determination method of mercury, arsenic element forms and their valence states" (the third draft for consultation), with a publicity period of one month (National Pharmacopoeia Committee) Jiangsu Medical Insurance Bureau issued a notice to cancel the medical consumables bonus of public medical institutions The notice clearly stipulates that, from 24:00 on December 30, 2019, the policy of difference rate and difference plus of medical consumables that can be charged separately by public medical and health institutions shall be cancelled, and the sales price shall be implemented according to the actual purchase price, and the price discount or other forms of discount given by the operator shall not be accepted in addition to the actual purchase price (Jiangsu medical insurance bureau) Recently, Jiangxi food and Drug Administration issued the fifth drug supervision sampling information notice of this year This sampling involves 32 batches of sterile varieties, 28 batches of non sterile drugs, 112 batches of Chinese herbal medicines and Chinese herbal pieces, and 1 batch of internal packaging materials A total of 80 varieties and 173 batches did not meet the requirements of the standard, and the non-compliance items included character, identification, inspection, content determination, etc (Jiangxi food and Drug Administration) According to the Taiyuan medical insurance bureau, Taiyuan recently reported a number of cases of illegal collection of medical insurance fees by hospitals, this time reported a total of 12 medical institutions, including 6 private medical institutions and 6 public medical institutions (Taiyuan medical insurance bureau) On December 18, Jinhua market Bureau said on its official website that the notice of Jinhua City on simplifying the examination and approval of class B over-the-counter drug business was officially implemented this month, and the examination and approval procedures for class B over-the-counter drug business were further simplified On the morning of December 13, the city successfully issued the first "application + commitment" drug business license (Jinhua market Bureau) On September 19, Penguin almond, a one-stop medical service platform, announced that it was gradually completing the building of Shenzhen's urban medical model, with a complete layout of various types of businesses, including primary medical care, comprehensive clinics, operation centers, specialized clinics, satellite clinics and enterprise clinics At the same time, we have completed the acquisition of 25 clinics of "Zhengfu oral", a chain dental institution in Shenzhen This acquisition is also an important part of further practice and improvement of specialty layout in Shenzhen urban medical model (Sina Medical News) Recently, Fujifilm plans to acquire Hitachi's medical imaging business, with an amount of 170 billion yen, equivalent to about 10.9 billion yuan The purpose of Fujifilm's acquisition is to be able to compete with GPS giants (GE, Philips, Siemens) in the future (cypress blue instrument) On December 16 and 17, the US FDA website issued three recall notices, Ge, Medtronic and cook medical respectively recalled relevant medical device products (cypress blue instrument) On Tuesday, Geely's hepatitis C drug vosevi was approved for sale in China Vosevi is a fixed dose compound composed of sophibuvir, vepatavir and foxirivir, which is known as "Jisi generation" in the industry In China, vosevi was included in the first batch of clinically urgent overseas drugs in March 2019 In June 2019, Gilead submitted the application for listing of the drug, and it took six months from the application for listing to today's approval (medicine cube) Novartis announced that it would terminate the acquisition of stu agonist adu-s100 from aduro, mainly with Novartis own PD-1 antibody spartalizumab, and the development of combination therapy with Squibb yevoy, but aduro is also ready to continue to develop the product and keytruda in the second phase of clinical treatment of head and neck cancer (source of us and Chinese Medicine) On the 18th local time, Boehringer Ingelheim and pharmaxis announced that their SSAO / VAP-1 inhibitor Bi 1467335 had no direct failure in the latest clinical research, but due to the interaction between the drug and other drugs, they decided to give up the drug for the research and development of fatty liver disease (Sina Medical News) Today, epizyme announced that the FDA advisory committee on oncology drugs voted 11:0 in favor of tazemetostat, the "first in class" EZH2 inhibitor developed by the company, to treat metastatic / locally advanced epithelioid sarcoma that is not suitable for surgical treatment Tazemetostat's new drug application has been qualified for FDA's priority review and is expected to receive a response by January 23 next year (yaomingkant) Today, GSK announced that its intravenous infusion therapy, benlysta, reached the primary and all secondary end points of its phase 3 trial bliss-ln in patients with lupus nephritis GlaxoSmithKline plans to submit regulatory applications for the indication in the first half of 2020 At present, benlysta is the only biological product approved for the treatment of lupus erythematosus (yaomingkant) Seattle genetics today announced that the FDA has granted its her specific oral small molecule tyrosine kinase inhibitor, tucatinib, a breakthrough therapy, to treat unresectable locally advanced or metastatic HER2 positive breast cancer patients with trastuzumab and capecitabine Seattle genetics plans to submit a new drug application to the FDA in the first quarter of 2020 (yaomingkant) Lilly announced Monday that it will launch a long-term real world study of migraine drug emgality, code named triumph, to compare the preventive effect of emgality and other preventive therapies on migraine patients under the real world health care system (medicine cube) The consistency evaluation of quality and efficacy of generic drugs in Luoxin pharmaceutical industry was reported again After three years of hard work, the product captopril tablet of rohin Pharmaceutical Co., Ltd was approved by the State Drug Administration today and passed the conformity evaluation of generic drugs (Sina Medical News) Today, FDA approved padcev, developed jointly by Seattle genetics and astralas, for the treatment of locally advanced or metastatic urothelial cancer Padcev is an antibody conjugated drug targeting to the nectin-4 This approval is nearly four months ahead of the scheduled PDUFA date (yaomingkant) Recently, MSD announced that the FDA oncology drug advisory committee voted 9:4 in favor of its heavyweight PD-1 inhibitor keytruda in the treatment of certain high-risk non muscle invasive bladder cancer patients The SBLA of keytruda in the treatment of high-risk NMIBC patients has obtained the priority review qualification granted by the US FDA, and MSD expects the FDA to respond in January next year (yaomingkant) Recently, the listing application of nilaparil, a new PARP inhibitor of zaiding pharmaceutical, has been changed to "under approval" It is expected to be approved for listing this month The indication is to maintain the treatment for adult patients with recurrent epithelial ovarian cancer, salpingocarcinoma or primary peritoneal ovarian cancer who have been completely or partially relieved by platinum chemotherapy (CPHL Pharma online)